Analysis of thrombotic factors in severe acute respiratory syndrome (SARS) patients [3]

Thrombosis and Haemostasis

Volumn 96, Issue 1, 2006, Pages 100-101

  Wu, Ya Ping ^a,b   Wei, Ran ^a   Liu, Zhong Hua ^c   Chen, Biao ^d   Lisman, Ton ^b   Ren, Dao Ling ^a   Han, Ji Ju ^a   Xia, Zuo Li ^a   Zhang, Fu Sheng ^e   Xu, Wen Bo ^c   Preissner, Klaus T ^f   de Groot, Philip G ^b  

^a TAISHAN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e Department of Medicine   (China)

^f JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPLASTIN; VITRONECTIN; VON WILLEBRAND FACTOR;

ADULT; ANALYSIS OF VARIANCE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CHINA; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; LETTER; LUNG LAVAGE; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERE ACUTE RESPIRATORY SYNDROME; STATISTICAL SIGNIFICANCE; STREPTOCOCCUS PNEUMONIA; THORAX RADIOGRAPHY;

ADULT; BIOLOGICAL MARKERS; BLOOD COAGULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; SEVERE ACUTE RESPIRATORY SYNDROME; THROMBOPHILIA;

EID: 33746741028     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH05-12-0827     Document Type: Letter

References (15)

1. Ng KH, et al. Pulmonary artery thrombosis in a patient with severe acute respiratory syndrome. Postgrad Med J 2005; 81: e3.
2. Wu YP, et al. SARS in Hong Kong. N Engl J Med 2003; 349: 708-9.
3. Lang ZW, et al. A clinicopathological study of three cases of SARS. Pathology 2003; 35: 526-31.
4. Rezaie AR. Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem 2001; 276: 15567-70.
5. World Health Organization (WHO). Severe acute respiratory syndrome (SARS). Wkly Epidemiol Rec 2003; 78: 81-3.
6. Muller MP, et al. Can routine laboratory tests discriminate between severe acute respiratory syndrome and other causes of community-acquired pneumonia? Clin Infect Dis 2005; 40: 1079-86.
7. Greiner M. Two-graph receiver operating characteristic (TG-ROC): update version supports optimisation of cut-off values that minimise overall misclassification costs. J Immunol Methods 1996; 191: 93-4.
8. CMDT Users Manual, Institute for Parasitology and Tropical Veterinary Medicine, Freie Universität, Berlin, Germany; Available by e-mail: cmdtχmx.net.
9. Henderson AR. Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristic curve analysis. Ann Clin Biochem 1993; 30: 521-39.
10. Tang BS, et al. Comparative host gene transcription by microarray analysis early after infection of the Huh7 cell line by SARScoronavirus and human coronavirus 229E. J Virol 2005; 79: 6180-93.
11. Wada H, et al. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients. Am J Hematol 2003; 72: 1-7.
12. Lijnen HR. Pleiotropic, functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3: 35-45.
13. Chavakis T, et al. Inhibition of platelet adhesion and aggregation by a defined region (Gly-486-Lys-502) of high molecular weight kininogen. J Biol Chem 2002; 26: 23157-64.
14. Reheman A, et al. Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation. J Thromb Haemost 2005; 3: 875-83.
15. Wu YP, et al. Fibrin-incorporated vitronectin is involved in platelet adhesion and thrombus formation through homotypic interactions with platelet-associated vitronectin. Blood 2004; 104: 1034-41.